Trump DOJ Seeks Court Pause on Lawsuits Challenging FDA Approval of Abortion Pill Mifepristone

What's happening

The Department of Justice under the Trump administration has formally requested a court-ordered pause on ongoing lawsuits that challenge the U.S. Food and Drug Administration's approval of the abortion pill mifepristone. This move comes amid an active FDA review of the drug’s safety profile, with the DOJ arguing that legal proceedings should wait until the agency completes its evaluation. The DOJ’s memorandum, filed recently, specifically targets lawsuits filed by Texas and Florida, which contest the FDA’s initial approval of mifepristone in 2000 and subsequent changes to its usage guidelines.

Mifepristone, approved by the FDA over two decades ago, is a medication used to induce abortion during early pregnancy. Its approval and use have been contentious, with several states seeking to restrict access through legal challenges. The current lawsuits argue that the FDA’s approval process was flawed and that the drug poses significant health risks. The DOJ counters that these lawsuits threaten to disrupt the FDA’s methodical review process and could result in premature judicial decisions that undermine federal regulatory authority.

The DOJ’s memorandum underscores concerns that ongoing litigation could interfere with the FDA’s ability to conduct a thorough and orderly safety review. According to the DOJ, halting these lawsuits temporarily would allow the agency to complete its evaluation without external pressure or legal complications. This request highlights the ongoing tension between state-level efforts to limit abortion access and the federal government’s role in regulating drug safety. It also reflects the broader national debate over abortion rights and the legal frameworks that govern reproductive health.

Key figures in this situation include the Trump administration’s Department of Justice, the FDA, and state governments such as Texas and Florida that have initiated lawsuits against the drug’s approval. Additionally, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary have publicly committed to reviewing safety concerns related to mifepristone. Some lawmakers, including Senator Josh Hawley, have expressed frustration with the FDA’s pace, noting that the agency remains in the early stages of data collection and has yet to analyze significant safety data.

What's at stake

The stakes of this legal and regulatory battle are significant. Women seeking abortion care, healthcare providers, and advocacy groups are directly affected by potential changes to mifepristone’s availability. Opponents of the drug argue that its use endangers women’s health and the lives of unborn children, citing reports of serious adverse events such as hemorrhage and infection in over 10% of users. Supporters emphasize the importance of maintaining access to safe and effective abortion options, warning that legal restrictions could limit reproductive rights and healthcare access.

Previous legal challenges to mifepristone have also involved the Trump DOJ, which sought to pause lawsuits questioning the FDA’s Risk Evaluation and Mitigation Strategies (REMS) for the drug. Critics of the DOJ’s approach argue that the government has not adequately defended the legality of FDA actions and that ongoing legal battles create uncertainty for patients and providers. The courts have yet to issue definitive rulings on these matters, leaving the regulatory status of mifepristone in a state of flux.

The outcome of this case could have lasting implications for abortion access in the United States, as well as for the FDA’s authority to regulate medications amid politically charged challenges. If the court grants the DOJ’s request for a pause, the FDA’s review process may proceed without immediate judicial interference, potentially leading to updated safety guidelines or reaffirmation of the drug’s approval. Conversely, if lawsuits proceed, they could result in restrictions or revocations that affect millions of women nationwide.

Looking ahead, observers will be closely watching for decisions from U.S. District Judge David C. Joseph, who has not yet indicated when he will rule on the DOJ’s request. The timeline for the FDA’s review remains uncertain, and legislative efforts, such as those introduced by Senator Hawley, may influence the regulatory landscape. The interplay between federal regulatory review, state legal actions, and political pressures will continue to shape the future of mifepristone’s availability and abortion access more broadly.

Why it matters

The DOJ seeks to pause lawsuits to allow the FDA to complete its safety review without judicial disruption. Legal challenges from Texas and Florida could prematurely alter the FDA’s longstanding approval of mifepristone. The ongoing litigation highlights the conflict between federal drug regulation and state-level abortion restrictions.

Women’s health and access to abortion services are directly impacted by the outcome of these legal and regulatory processes. The FDA’s review timeline is unclear, raising concerns among lawmakers and stakeholders about the pace of evaluation.

Key facts & context

Mifepristone was approved by the FDA in 2000 for use in medical abortions. The Trump administration’s DOJ filed a memorandum requesting a court-mandated pause on lawsuits challenging this approval. The lawsuits come from states including Texas and Florida, contesting both the initial approval and later modifications to mifepristone’s use.

The DOJ argues that ongoing litigation could disrupt the FDA’s orderly review process and lead to premature judicial decisions. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary have committed to reviewing safety concerns related to mifepristone. Recent data indicate that over 10% of women using mifepristone may experience serious adverse events such as hemorrhage or infection.

Senator Josh Hawley has introduced legislation aimed at revoking mifepristone’s FDA approval and providing legal remedies for those harmed by the drug. Previous DOJ actions have sought to pause legal challenges related to the FDA’s Risk Evaluation and Mitigation Strategies for mifepristone. U.S. District Judge David C. Joseph has not yet ruled on the DOJ’s current request for a pause in the lawsuits.

The legal battle over mifepristone reflects broader national debates over abortion access and federal versus state regulatory authority.

Timeline & key developments

2026-03-16: Trump DOJ Seeks Pause on Abortion Pill Lawsuit Amid Safety Review. Additional reporting on this topic is available in our broader archive and will continue to shape this timeline as new developments emerge.

Primary sources

• courtlistener.com document
• finance.senate.gov document

Further reading & references

• (Additional background links will appear here as we cover this topic.)